Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

James Graham, CEO of Recce Pharmaceuticals (RCE), discusses the progress of their new class of synthetic anti-infectives. Under the TGA's special access scheme, their compound demonstrated safety and efficacy against antibiotic-resistant infections. Topically and intravascularly administered compounds offer solutions for diabetic foot ulcers, post-surgery infections, sepsis, and more. Their R&D advances support plans for both intravascular and topical applications. A constrained capital raising, backed by a top-tier institution, aims to secure funds for upcoming programs. Recce Pharmaceuticals addresses the urgent issue of antibiotic resistance and aims to deliver effective treatments for various medical needs.

Ausbiz Interview - Recce Pharmaceuticals (RCE) positive patients update